v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Cash flows from operating activities:    
Net loss $ (3,460,310) $ (756,300)
Adjustments to reconcile net loss to net cash used in operating activities:    
General and administrative costs 1,506,836
(Increase) decrease in -    
Advances on research and development contract services (246,435)
Accrued interest receivable 14,367
Prepaid insurance (8,672) 19,889
Other prepaid expenses and current assets (29,871) 8,295
Increase (decrease) in -    
Accounts payable and accrued expenses (27,845) 15,319
Research and development contract liabilities 198,114 (70,252)
Net cash used in operating activities (2,068,183) (768,682)
Cash flows from financing activities:    
Proceeds from sale of common stock in direct equity offering, net of offering costs 3,689,761
Payment of deferred offering costs (55,850)
Exercise of common stock warrants 17,100
Exercise of common stock options 101,000
Payment of public offering costs (10,467)
Net cash provided by (used in) financing activities 3,797,394 (55,850)
Cash:    
Net increase (decrease) 1,729,211 (824,532)
Balance at beginning of period 5,069,266 2,598,864
Balance at end of period 6,798,477 1,774,332
Supplemental disclosures of cash flow information:    
Interest 2,944
Income taxes

Source